Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia
Background Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in adults ≥60 years. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modele...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2523602 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471488963379200 |
|---|---|
| author | Ru Han Jorge A. Gomez Chau Ngo Quy Otavio Cintra Desiree van Oorschot Adriana Guzman-Holst |
| author_facet | Ru Han Jorge A. Gomez Chau Ngo Quy Otavio Cintra Desiree van Oorschot Adriana Guzman-Holst |
| author_sort | Ru Han |
| collection | DOAJ |
| description | Background Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in adults ≥60 years. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modeled the burden of RSV among adults ≥60 years in India and Southeast Asia, and the potential impact of RSV vaccination.Methods A Markov model was adapted to the settings of India, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. RSV ARI cases, LRTD-associated hospitalizations, pneumonia, and deaths were tallied over a five-year period. Impact of adjuvanted RSVPreF3 vaccination with 30% and 70% coverage was assessed by calculation of incremental differences versus no vaccination.Results A total of 73.9 million RSV ARI were projected to occur in adults ≥60 years living in the selected countries. Numbers of hospitalizations, pneumonia, and deaths were approximately 3.1 million, 2.9 million, and 294,000, respectively. Adjuvanted RSVPreF3 vaccination with a 30% coverage could prevent 8.6 million RSV ARI, 460,255 hospitalizations, 423,659 pneumonia, and 43,693 deaths over 5 years.Conclusions The projected burden of RSV was substantial in India and Southeast Asia, and could greatly be alleviated through adjuvanted RSVPreF3 vaccination of adults ≥60 years. |
| format | Article |
| id | doaj-art-8a32ee9a5cf34d0494ae4df46fc2ed36 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-8a32ee9a5cf34d0494ae4df46fc2ed362025-08-20T03:24:48ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0124157057710.1080/14760584.2025.2523602Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast AsiaRu Han0Jorge A. Gomez1Chau Ngo Quy2Otavio Cintra3Desiree van Oorschot4Adriana Guzman-Holst5Epidemiology and Health Outcomes, GSK, Wavre, BelgiumEpidemiology and Health Outcomes, GSK, Buenos Aires, ArgentinaRespiratory Medicine Department, Tam Anh General Hospital, Hanoi, VietnamMedical Affairs, GSK, Sao Paulo, BrazilEpidemiology and Health Outcomes, GSK, Wavre, BelgiumEpidemiology and Health Outcomes, GSK, Wavre, BelgiumBackground Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in adults ≥60 years. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modeled the burden of RSV among adults ≥60 years in India and Southeast Asia, and the potential impact of RSV vaccination.Methods A Markov model was adapted to the settings of India, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. RSV ARI cases, LRTD-associated hospitalizations, pneumonia, and deaths were tallied over a five-year period. Impact of adjuvanted RSVPreF3 vaccination with 30% and 70% coverage was assessed by calculation of incremental differences versus no vaccination.Results A total of 73.9 million RSV ARI were projected to occur in adults ≥60 years living in the selected countries. Numbers of hospitalizations, pneumonia, and deaths were approximately 3.1 million, 2.9 million, and 294,000, respectively. Adjuvanted RSVPreF3 vaccination with a 30% coverage could prevent 8.6 million RSV ARI, 460,255 hospitalizations, 423,659 pneumonia, and 43,693 deaths over 5 years.Conclusions The projected burden of RSV was substantial in India and Southeast Asia, and could greatly be alleviated through adjuvanted RSVPreF3 vaccination of adults ≥60 years.https://www.tandfonline.com/doi/10.1080/14760584.2025.2523602Adjuvanted RSVPreF3IndiaMarkov modelpublic health impactRSVSoutheast Asia |
| spellingShingle | Ru Han Jorge A. Gomez Chau Ngo Quy Otavio Cintra Desiree van Oorschot Adriana Guzman-Holst Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia Expert Review of Vaccines Adjuvanted RSVPreF3 India Markov model public health impact RSV Southeast Asia |
| title | Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia |
| title_full | Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia |
| title_fullStr | Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia |
| title_full_unstemmed | Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia |
| title_short | Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia |
| title_sort | potential public health impact of the adjuvanted rsvpref3 vaccine in adults aged 60 years and older results from a modeling study in india and southeast asia |
| topic | Adjuvanted RSVPreF3 India Markov model public health impact RSV Southeast Asia |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2025.2523602 |
| work_keys_str_mv | AT ruhan potentialpublichealthimpactoftheadjuvantedrsvpref3vaccineinadultsaged60yearsandolderresultsfromamodelingstudyinindiaandsoutheastasia AT jorgeagomez potentialpublichealthimpactoftheadjuvantedrsvpref3vaccineinadultsaged60yearsandolderresultsfromamodelingstudyinindiaandsoutheastasia AT chaungoquy potentialpublichealthimpactoftheadjuvantedrsvpref3vaccineinadultsaged60yearsandolderresultsfromamodelingstudyinindiaandsoutheastasia AT otaviocintra potentialpublichealthimpactoftheadjuvantedrsvpref3vaccineinadultsaged60yearsandolderresultsfromamodelingstudyinindiaandsoutheastasia AT desireevanoorschot potentialpublichealthimpactoftheadjuvantedrsvpref3vaccineinadultsaged60yearsandolderresultsfromamodelingstudyinindiaandsoutheastasia AT adrianaguzmanholst potentialpublichealthimpactoftheadjuvantedrsvpref3vaccineinadultsaged60yearsandolderresultsfromamodelingstudyinindiaandsoutheastasia |